CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?

Positive
AI Analysis

Summary

Morgan Stanley nearly doubled its price target for CRISPR Therapeutics, indicating increased analyst confidence in the gene-editing company's prospects.

Importance:3/10
Sentiment:
0.60
price_targetanalyst_upgradegene_editingcrispr
Related Companies

Read the original article

Published by yahoo_finance on July 30, 2026 9:58 PM

Read Original